250 related articles for article (PubMed ID: 22403494)
1. Albumin for end-stage liver disease.
Lee JS
Korean J Intern Med; 2012 Mar; 27(1):13-9. PubMed ID: 22403494
[TBL] [Abstract][Full Text] [Related]
2. Drug insight: the role of albumin in the management of chronic liver disease.
Wong F
Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4(1):43-51. PubMed ID: 17203088
[TBL] [Abstract][Full Text] [Related]
3. Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?
Bernardi M; Caraceni P; Navickis RJ
Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):191-192. PubMed ID: 28004601
[No Abstract] [Full Text] [Related]
4. Review article: albumin for circulatory support in patients with cirrhosis.
Ginès P; Guevara M; De Las Heras D; Arroyo V
Aliment Pharmacol Ther; 2002 Dec; 16 Suppl 5():24-31. PubMed ID: 12423450
[TBL] [Abstract][Full Text] [Related]
5. Albumin infusion in liver cirrhotic patients.
Rena NM; Wibawa ID
Acta Med Indones; 2010 Jul; 42(3):162-8. PubMed ID: 20724771
[TBL] [Abstract][Full Text] [Related]
6. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
7. [The use of albumin infusion in decompensated liver cirrhosis].
Schmidt LE; Ring-Larsen H
Ugeskr Laeger; 2002 Feb; 164(9):1196-202. PubMed ID: 11899505
[TBL] [Abstract][Full Text] [Related]
8. The use of human albumin for the treatment of ascites in patients with liver cirrhosis: item of safety, facts, controversies and perspectives.
Facciorusso A; Nacchiero MC; Rosania R; Laonigro G; Longo N; Panella C; Ierardi E
Curr Drug Saf; 2011 Sep; 6(4):267-74. PubMed ID: 22129322
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.
Bañares R; Nevens F; Larsen FS; Jalan R; Albillos A; Dollinger M; Saliba F; Sauerbruch T; Klammt S; Ockenga J; Pares A; Wendon J; Brünnler T; Kramer L; Mathurin P; de la Mata M; Gasbarrini A; Müllhaupt B; Wilmer A; Laleman W; Eefsen M; Sen S; Zipprich A; Tenorio T; Pavesi M; Schmidt HH; Mitzner S; Williams R; Arroyo V;
Hepatology; 2013 Mar; 57(3):1153-62. PubMed ID: 23213075
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial.
García-Compean D; Blanc P; Larrey D; Daures JP; Hirtz J; Mendoza E; Maldonado H; Michel H
Ann Hepatol; 2002; 1(1):29-35. PubMed ID: 15114293
[TBL] [Abstract][Full Text] [Related]
11. Treatment of persistent/medically refractory covert hepatic encephalopathy with the molecular adsorbent recirculating system.
Leise MD; Leung N; El-Zoghby Z; Gonzalez Gonzalez HC; Cerhan JH; Nyberg SL
Liver Transpl; 2014 Jul; 20(7):867-8. PubMed ID: 24700610
[No Abstract] [Full Text] [Related]
12. Albumin: Indications in chronic liver disease.
Tufoni M; Zaccherini G; Caraceni P; Bernardi M
United European Gastroenterol J; 2020 Jun; 8(5):528-535. PubMed ID: 32213034
[TBL] [Abstract][Full Text] [Related]
13. Is there still a need for albumin infusions to treat patients with liver disease?
Ginès P; Arroyo V
Gut; 2000 May; 46(5):588-90. PubMed ID: 10764695
[No Abstract] [Full Text] [Related]
14. AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis.
;
Dig Liver Dis; 2016 Jan; 48(1):4-15. PubMed ID: 26802734
[TBL] [Abstract][Full Text] [Related]
15. [Albumin substitution : A review of the indications in general internal medicine].
Dumas D; Benmachiche M; Gachoud D
Rev Med Suisse; 2021 Nov; 17(760):2022-2026. PubMed ID: 34817939
[TBL] [Abstract][Full Text] [Related]
16. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
Umgelter A; Reindl W; Wagner KS; Franzen M; Stock K; Schmid RM; Huber W
Crit Care; 2008; 12(1):R4. PubMed ID: 18197961
[TBL] [Abstract][Full Text] [Related]
17. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations.
Pericleous M; Sarnowski A; Moore A; Fijten R; Zaman M
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):e10-8. PubMed ID: 26671516
[TBL] [Abstract][Full Text] [Related]
18. [Use of albumin : State of the art].
Mayerhöfer T; Wiedermann CJ; Joannidis M
Med Klin Intensivmed Notfmed; 2021 Nov; 116(8):655-664. PubMed ID: 34618163
[TBL] [Abstract][Full Text] [Related]
19. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites.
Umgelter A; Reindl W; Franzen M; Lenhardt C; Huber W; Schmid RM
Intensive Care Med; 2009 Jan; 35(1):152-6. PubMed ID: 18802688
[TBL] [Abstract][Full Text] [Related]
20. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.
Alessandria C; Elia C; Mezzabotta L; Risso A; Andrealli A; Spandre M; Morgando A; Marzano A; Rizzetto M
Dig Liver Dis; 2011 Nov; 43(11):881-6. PubMed ID: 21741331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
